Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Atrovent® Inhaletten

Study type: Observational

Funder types: Industry

Identifiers

NCT02238145

244.2492

Details and patient eligibility

About

To obtain further information on the tolerability and efficacy of Atrovent® inhaletten® in the treatment of chronic obstructive airways disease under conditions of daily practice

Enrollment: 660 patients

Sex: All

Ages: 30+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primarily patients of both gender, older than 30 years,who suffer from chronic obstructive airways disease
• Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion criteria

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhaletten®

Trial design

660 participants in 1 patient group

Chronic Obstructive Airways Disease

Treatment:

Drug: Atrovent® Inhaletten